• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Active Biotech

5.30 SEK+0.38 %15.7. klo 18.25
Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.47 %
-13.40 %
-26.18 %
+21.00 %
+15.22 %
-69.91 %
-78.89 %
-88.33 %
-98.72 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Read more
Market cap
139.71M SEK
Turnover
150.06K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.8.
2026

Interim report Q2'26

5.11.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

Regulatory press release30.06.2026 klo 09.30

Number of shares and votes in Active Biotech

Active Biotech
Regulatory press release28.05.2026 klo 09.30

Active Biotech announces timetable for reverse share split

Active Biotech
Regulatory press release20.05.2026 klo 19.30

Annual General Meeting of Active Biotech AB

Active Biotech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release13.05.2026 klo 12.30

European regulatory approval obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech, Oncode and HOVON

Active Biotech
Press release08.05.2026 klo 11.14

Redeye: Active Biotech (Q1 Review): Intensified Focus on Business Development

Active Biotech
Regulatory press release07.05.2026 klo 09.30

Active Biotech Interim Report Q1 2026

Active Biotech
Press release20.04.2026 klo 12.30

Active Biotech publishes results from the LION study on ocular absorption and distribution of laquinimod in the eye

Active Biotech
Regulatory press release17.04.2026 klo 15.30

NOTICE OF ANNUAL GENERAL MEETING

Active Biotech
Regulatory press release01.04.2026 klo 10.30

Annual Report 2025 Active Biotech AB (publ)

Active Biotech
Press release13.02.2026 klo 14.08

Redeye: Active Biotech (Q4 Review): Tasqinimod Recruiting Again

Active Biotech
Regulatory press release12.02.2026 klo 09.30

Active Biotech Year End Report 2025

Active Biotech
Press release10.02.2026 klo 12.30

Active Biotech receives positive feedback on its clinical study with tasquinimod in myelofibrosis

Active Biotech
Regulatory press release30.01.2026 klo 12.30

Number of shares and votes in Active Biotech

Active Biotech
Regulatory press release21.01.2026 klo 17.15

Active Biotech's nomination committee appointed

Active Biotech
Regulatory press release10.12.2025 klo 21.00

Active Biotech announces outcome in the rights issue

Active Biotech
Press release25.11.2025 klo 11.00

Active Biotech’s patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Active Biotech
Regulatory press release25.11.2025 klo 09.30

The subscription period in Active Biotech’s rights issue begins today

Active Biotech
Press release24.11.2025 klo 10.30

Positive preclinical tasquinimod data in myelofibrosis published in Blood Advances

Active Biotech
Regulatory press release20.11.2025 klo 16.45

Active Biotech publishes information document regarding rights issue

Active Biotech
Regulatory press release19.11.2025 klo 13.00

Extraordinary General Meeting of Active Biotech AB

Active Biotech